Whitehawk Therapeutics (WHWK) Net Margin (2018 - 2025)
Historic Net Margin for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q1 2025 value amounting to 201.92%.
- Whitehawk Therapeutics' Net Margin rose 1397200.0% to 201.92% in Q1 2025 from the same period last year, while for Sep 2025 it was 717.23%, marking a year-over-year decrease of 4711800.0%. This contributed to the annual value of 245.13% for FY2024, which is 249100.0% up from last year.
- Latest data reveals that Whitehawk Therapeutics reported Net Margin of 201.92% as of Q1 2025, which was up 1397200.0% from 252.42% recorded in Q4 2024.
- Over the past 5 years, Whitehawk Therapeutics' Net Margin peaked at 114.21% during Q4 2021, and registered a low of 4563.33% during Q1 2021.
- Moreover, its 5-year median value for Net Margin was 266.18% (2022), whereas its average is 580.18%.
- Within the past 5 years, the most significant YoY rise in Whitehawk Therapeutics' Net Margin was 39626800bps (2022), while the steepest drop was -1519600bps (2022).
- Quarter analysis of 5 years shows Whitehawk Therapeutics' Net Margin stood at 114.21% in 2021, then crashed by -133bps to 266.18% in 2022, then rose by 3bps to 257.18% in 2023, then increased by 2bps to 252.42% in 2024, then increased by 20bps to 201.92% in 2025.
- Its Net Margin was 201.92% in Q1 2025, compared to 252.42% in Q4 2024 and 173.95% in Q3 2024.